Novartis AG (NVSEF) stock analysis
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
StockData Score
Prices as of Nov 4, 2026How the score works
Weak7 of 30 checks passed
Novartis passes 7 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 2/6
- Past performance
- 4/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
Return on equity over 15%
Return on equity was 33.5% over the last twelve months and averaged 27.0% over five years.
Return on capital over 10%
Return on invested capital was 43.5%, above the 10% that usually covers the cost of capital.
Earnings grew over 5 years
Net income grew 11.6% a year on average over the last five fiscal years.
EPS growing 10%+ a year
Diluted EPS grew 31.1% a year over the last three fiscal years.
What to watch
Short-term assets don't cover short-term debts
Current assets are 0.86 times current liabilities.
No dividend
Novartis has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth2/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growing 10%+ a year
Diluted EPS grew 31.1% a year over the last three fiscal years.
Earnings growth accelerating
Net income grew 17.1% over the last twelve months, against a 5-year average of 11.6% a year.
Growth against the industry
Needs revenue for this year and last.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance4/6
Return on equity over 15%
Return on equity was 33.5% over the last twelve months and averaged 27.0% over five years.
Return on capital over 10%
Return on invested capital was 43.5%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Novartis's return on equity of 33.5% is above the Drugs median of -58.5%.
Earnings grew over 5 years
Net income grew 11.6% a year on average over the last five fiscal years.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest well covered
Operating income covers interest expense 15.4 times.
Short-term assets don't cover short-term debts
Current assets are 0.86 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Novartis has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Novartis. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $301.91M
- Value traded per 1% price move
- $236.35M
Downside
Low risk
- Typical loss in a bad month
- 11.9%
- Volatility (annualized)
- 27%
- Sharpe ratio, 1 year
- 0.90
- Beta to the S&P 500 (5Y)
- 0.42
Typical bad-month loss, week by week
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Gross profit | +10.5% | +10.5% | +4.3% | +2.7% | |
| Operating income | +21.3% | +30.5% | +11.7% | +7.0% | |
| Net income | +17.1% | +26.2% | +11.6% | -2.4% | |
| EPS, diluted | +21.8% | +31.1% | +15.2% | -0.2% | |
| Free cash flow | +8.3% | +9.7% | +7.3% | +6.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 14.4% | 31.0% | |
| Return on assets | – | 6.6% | 13.1% | |
| Current ratio | 1.12 | 0.90 | 1.12 | |
| Interest coverage | 11.7× | 11.7× | 15.4× | |
| Diluted shares | 2.40B | 2.30B | 1.96B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Novartis generated $80.53B from operations and spent $83.50B on capital expenditure, dividends and share buybacks. 7% of that went back into the business.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$13.98B
- Cash generatingOperating cash flow above zero$19.14B
- Return on assets improvedROA up on the prior year11.9% → 13.7%
- Earnings backed by cashOperating cash flow above net income$19.14B vs $13.98B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.04 → 1.12
- No dilutionShare count did not rise2.04B → 1.96B
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –
See a number that looks wrong?